Xeris Biopharma Holdings (XERS) Earnings Analysis

Xeris Biopharma Holdings (XERS) next reports earnings on 2026-08-06, consensus EPS 0.02 USD. Last quarter (2026-05-07) it beat with EPS 0.01 USD vs -0.00274 USD est (+465%). It has beaten estimates in 6/7 recent quarters (86%). Trailing P/E 118.36.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does XERS next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate0.02 USD
Revenue estimate0.09B

XERS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-070.01 USD-0.00274 USD+465%Beat
2026-03-020.06 USD0.03 USD+100%Beat
2025-11-060.0035 USD0.01 USD-65%Miss
2025-05-08-0.06 USD-0.07 USD+14.3%Beat
2025-03-06-0.03 USD-0.08 USD+62.5%Beat
2024-11-08-0.06 USD-0.09 USD+33.3%Beat
2024-08-08-0.1 USD-0.11 USD+9.1%Beat

Beat rate: 6/7 (86%) over reported quarters with consensus data.

XERS valuation and analyst view

Trailing P/E118.36
Trailing EPS0.07042 USD
Price / book109.83
Dividend yield0.00%
Market cap1.46B
Analyst consensusBuy (9 buy / 1 hold / 0 sell)
Avg price target13.5 USD

Related research pages

Frequently asked questions

When is Xeris Biopharma Holdings (XERS)'s next earnings date?

Xeris Biopharma Holdings is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.02 USD and revenue estimate of 0.09B.

Did XERS beat earnings last quarter?

In its 2026-05-07 report, XERS posted EPS of 0.01 USD versus a -0.00274 USD estimate — a beat of 465%.

What is XERS's earnings track record?

Over the last 7 reported quarters with consensus data, XERS beat estimates 6 times (86%).

What is XERS's current P/E ratio and EPS?

XERS trades at a trailing P/E of 118.36 on trailing EPS of 0.07041856730727233 USD.

What do analysts rate XERS?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 13.5 USD.